For patients presenting with slow growing PCa, defined according to the European Association of Urology (EAU) guidelines as clinically insignificant cancer (insPCa: Gleason score, GS < 7 and PSA < 10 ng/ml and max 2 cores) [3], immediate treatment is not recommended, rather management by active surveillance (AS) including re-biopsies in certain time frames [3]. The gene discussed is KLK3; the disease is posterior cortical atrophy.